Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.83 and traded as high as $1.27. Brainstorm Cell Therapeutics shares last traded at $1.20, with a volume of 48,261 shares trading hands.

Brainstorm Cell Therapeutics Stock Down 1.1%

The stock has a market capitalization of $13.09 million, a price-to-earnings ratio of -0.34 and a beta of 0.23. The firm has a fifty day moving average of $1.00 and a 200-day moving average of $0.84.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, research analysts forecast that Brainstorm Cell Therapeutics Inc. will post -3.01 EPS for the current fiscal year.

About Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).